China announces generic drug list to reduce pharmaceutical costs
Chinese government introduces initiative to enable generic drugs to enter market and reduce prices.
List view / Grid view
Chinese government introduces initiative to enable generic drugs to enter market and reduce prices.
The latest research and developments from Pharma and Biopharma industry experts.
Our culture media are the reliable and convenient choice for aseptic process simulation and include Ready-to-use and Dehydrated Culture Media to meet the specific needs in the pharmaceutical industry.
Having a holistic data infrastructure in place can not only save time by providing key real-time information and money through readily-accessible, enterprise-wide intelligence, it can also ensure stress-free operations.
The company has announced a recall of products which were intended to be sterile after a lack of sterility assurance.
This in-depth focus looks into industrial workflow processes and also how nature can provide inspiration for drug delivery.
Researchers have found that many pharmaceutical products contain inactive ingredients which can be dangerous to patients.
Comparative human in-vivo study of an immediate release tablet over-encapsulated by gelatin and hydroxypropyl methyl cellulose capsules –impact of dissolution rate on bioequivalence.
A study has predicted that the global biopharmaceutical contract manufacturing market will grow by 10.6 percent from 2017 to 2027.
Catalyst Pharmaceuticals Inc has sued the FDA to challenge the recent approval of a lower-cost rival drug.
How an inline vial management device is able to reject, retrieve for sampling, or reintroduce vials automatically during the loading/unloading process into pharmaceutical freeze-dryers.
Luxembourg and the Netherlands have been included in the mutual recognition agreement between the EU and the FDA in the US.
Lubricants have a far more wide-reaching impact on the characteristics of the finished tablet than merely easing their means of production. A study was carried out to investigate precisely what those effects were.
The EMA has accepted Prestige BioPharma’s marketing application for its trastuzumab biosimilar.
Heritage has recalled two of its injectable treatments after microbial growths were found.